Medical News

RSS

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, noted today that individual site, investigator-initiated results of an ongoing Phase 3 clinical trial of 99m-Tc-Tilmanocept (Lymphoseek) were presented at the American Head and Neck Society's 8th International Conference on Head and Neck Cancer (ICHNC), held in Toronto, July 21-25, 2012.

27 Jul 2012

Molina Healthcare reports net loss of $37.3 million for second quarter 2012

Molina Healthcare, Inc. today reported its financial results for the second quarter and six months ended June 30, 2012.

27 Jul 2012

Chevron announces PMTCT partnership to combat mother-to-child transmission of HIV in Africa

Chevron announced today at the 2012 International AIDS Conference (AIDS 2012) a partnership initiative with Pact, the Business Leadership Council (BLC), mothers2mothers and the Global Fund to aggressively combat crisis-level mother-to-child transmission of HIV in Nigeria, Angola and South Africa.

27 Jul 2012

High-dose IL-2 still the most effective treatment for patients with stage IV metastatic melanoma

Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., explores whether or not this regimen is still the most effective.

26 Jul 2012

Recent release: HHS officials discuss take away messages from AIDS 2012

The AIDS.gov blog provides video footage of a conversation between Howard Koh, assistant secretary for health for the U.S. Department of Health and Human Services (HHS) and Nils Daulaire, director of the Office of Global Affairs at HHS, which took place at the XIX International AIDS Conference. According to the blog, Daulaire discusses his role at the department and some of his take away messages from AIDS 2012.

26 Jul 2012

Uroplasty first quarter global sales increase 20% to $5.6 million

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the first quarter of fiscal 2013 ended June 30, 2012.

26 Jul 2012

Study highlights advantages of Baxano's iO-Flex system in performing lumbar spinal decompression

Baxano, Inc., the manufacturer of the innovative and cost-effective iO-Flex System, announced today the publication of a peer-reviewed study highlighting the advantages of the flagship iO-Flex technology in performing lumbar spinal decompression, a procedure that can be done with and without spinal fusion.

26 Jul 2012

Fusion of FGFR and TACC gene leads to glioblastoma

Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes.

26 Jul 2012

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Horizon Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).

26 Jul 2012

Preliminary findings from Protalex's PRTX-100 Phase 1b study on active rheumatoid arthritis

Protalex, Inc., a clinical stage biopharmaceutical company that is developing a class of drugs designed to treat a wide array of autoimmune and inflammatory diseases today announced preliminary findings from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study.

26 Jul 2012

Takeda, Sucampo file AMITIZA sNDA with FDA for treatment of opioid-induced constipation

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A. Inc. today announced the filing of a supplemental new drug application (sNDA) with the US Food and Drug Administration (FDA) seeking approval for a new indication for AMITIZA (lubiprostone) for the treatment of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain.

26 Jul 2012